Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTENAFINE HYDROCHLORIDE vs AMPHOTEC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Not significantly metabolized; undergoes minimal hepatic metabolism via CYP enzymes (unknown specific isoforms).
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Approximately 60–70% bound to plasma proteins, predominantly albumin.
>95% bound to albumin and alpha-1-acid glycoprotein.
Not well characterized due to minimal systemic absorption; estimated volume of distribution is very low, consistent with extensive tissue binding or limited distribution.
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
Topical: Systemic bioavailability is less than 5% following topical administration; oral bioavailability has not been established as drug is not used systemically.
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
No dose adjustment required; negligible systemic absorption.
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
No dose adjustment required; negligible systemic absorption.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
≥12 years: same as adult; <12 years: safety and efficacy not established; use only if clearly needed.
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
No specific adjustment; same as adult dosing; monitor for skin irritation.
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
None.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
For external use only.,Avoid contact with eyes, nose, mouth, and other mucous membranes.,Discontinue if irritation or sensitization occurs.,Not recommended for treatment of onychomycosis or scalp infections.
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
Hypersensitivity to butenafine hydrochloride or any components of the formulation.
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
No clinically significant food interactions reported. Butenafine is applied topically and systemic absorption is minimal, so dietary restrictions are not required.
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
Unknown if excreted in human milk; M/P ratio not established. Use with caution in nursing mothers; consider benefits vs risks.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
No dose adjustment required based on pharmacokinetic changes in pregnancy; topical application has minimal systemic absorption.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
Butenafine hydrochloride is a benzylamine antifungal with fungicidal activity against dermatophytes (e.g., Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum) and yeasts (Malassezia spp.). It inhibits squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis. Applied once or twice daily for 1–4 weeks depending on indication. For tinea pedis (athlete's foot), treatment should extend 1 week beyond resolution to prevent recurrence. Avoid occlusion unless directed; may increase irritation. Contraindicated in hypersensitivity to any component. For severe or resistant cases, consider combination with keratolytics (e.g., salicylic acid) to enhance penetration.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Apply butenafine cream exactly as prescribed: clean and dry the affected area before application.,Use enough medication to cover the affected skin and a small margin of healthy surrounding skin.,Wash your hands after applying, unless treating the hands.,Do not cover the treated area with bandages or dressings unless instructed by your doctor.,Complete the full course of treatment even if symptoms improve, to prevent recurrence.,Notify your doctor if no improvement after 2–4 weeks or if irritation, redness, or blistering occurs.,Avoid contact with eyes, mouth, nose, or broken skin; if accidental contact occurs, rinse with water.,Do not use for conditions other than those prescribed; butenafine is for external use only.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
"Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is primarily metabolized by CYP3A4 and CYP2C19. Butenafine, an antifungal agent, is also metabolized by CYP3A4. Concurrent use may inhibit the metabolism of butenafine, leading to increased systemic exposure and potential toxicity, including hepatotoxicity or QT prolongation."
"Ranolazine, an antianginal agent, inhibits CYP3A4 and CYP2D6, reducing the metabolism of Butenafine, an antifungal agent typically metabolized by these enzymes. This results in significantly elevated Butenafine serum concentrations, increasing the risk of systemic adverse effects such as hepatotoxicity and QT prolongation. Co-administration may lead to enhanced antifungal efficacy but also potential toxicity."
"Butenafine, an allylamine antifungal, inhibits squalene epoxidase, a key enzyme in ergosterol biosynthesis, leading to fungal cell death. Bepridil, a calcium channel blocker with class I antiarrhythmic properties, prolongs the QT interval by blocking cardiac potassium channels, increasing the risk of torsades de pointes. When combined, butenafine may further inhibit hERG potassium channels in cardiac myocytes, potentiating QT prolongation and elevating the risk of life-threatening ventricular arrhythmias, particularly in patients with preexisting QT prolongation or electrolyte abnormalities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTENAFINE HYDROCHLORIDE vs AMPHOTEC, answered by our medical review team.
BUTENAFINE HYDROCHLORIDE is a Antifungal that works by Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTENAFINE HYDROCHLORIDE and AMPHOTEC depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTENAFINE HYDROCHLORIDE is: 1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.. The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTENAFINE HYDROCHLORIDE and AMPHOTEC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTENAFINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.